90 related articles for article (PubMed ID: 21503962)
1. Ubiquitination and downregulation of ErbB2 and estrogen receptor-alpha by kinase inhibitor MP-412 in human breast cancer cells.
Suzuki T; Fujii A; Ochi H; Nakamura H
J Cell Biochem; 2011 Sep; 112(9):2279-86. PubMed ID: 21503962
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.
Suzuki T; Fujii A; Ohya J; Amano Y; Kitano Y; Abe D; Nakamura H
Cancer Sci; 2007 Dec; 98(12):1977-84. PubMed ID: 17888033
[TBL] [Abstract][Full Text] [Related]
4. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Xu W; Yuan X; Jung YJ; Yang Y; Basso A; Rosen N; Chung EJ; Trepel J; Neckers L
Cancer Res; 2003 Nov; 63(22):7777-84. PubMed ID: 14633703
[TBL] [Abstract][Full Text] [Related]
5. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
[TBL] [Abstract][Full Text] [Related]
6. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
[TBL] [Abstract][Full Text] [Related]
7. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
8. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.
Gougelet A; Bouclier C; Marsaud V; Maillard S; Mueller SO; Korach KS; Renoir JM
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):71-81. PubMed ID: 15862952
[TBL] [Abstract][Full Text] [Related]
10. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
11. Pentagalloylglucose inhibits estrogen receptor alpha by lysosome-dependent depletion and modulates ErbB/PI3K/Akt pathway in human breast cancer MCF-7 cells.
Hua KT; Way TD; Lin JK
Mol Carcinog; 2006 Aug; 45(8):551-60. PubMed ID: 16637063
[TBL] [Abstract][Full Text] [Related]
12. Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway.
St-Laurent V; Sanchez M; Charbonneau C; Tremblay A
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):23-37. PubMed ID: 15862947
[TBL] [Abstract][Full Text] [Related]
13. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
14. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.
Marx C; Yau C; Banwait S; Zhou Y; Scott GK; Hann B; Park JW; Benz CC
Mol Pharmacol; 2007 Jun; 71(6):1525-34. PubMed ID: 17392524
[TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Chen FL; Xia W; Spector NL
Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
[TBL] [Abstract][Full Text] [Related]
16. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
17. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
[TBL] [Abstract][Full Text] [Related]
18. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
19. Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis.
Zhou Y; Brattain MG
Cancer Res; 2005 Jul; 65(13):5848-56. PubMed ID: 15994962
[TBL] [Abstract][Full Text] [Related]
20. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer.
Chu I; Arnaout A; Loiseau S; Sun J; Seth A; McMahon C; Chun K; Hennessy B; Mills GB; Nawaz Z; Slingerland JM
J Clin Invest; 2007 Aug; 117(8):2205-15. PubMed ID: 17627304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
